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Background/aim: We aimed to compare the results of WaveLight Allegretto Wave Eye-Q 400 Hz and Technolas 217z100 excimer lasers
in the treatment of mixed astigmatism.
Materials and methods: Forty-nine patients who underwent laser in situ keratomileusis for mixed astigmatism were included in this
retrospective study. Twenty-eight eyes of 21 patients were treated with WaveLight and 46 eyes of 28 patients were treated with the
Technolas excimer laser. The patients’ visual acuities and refractive values were evaluated on postoperative day 1 and at 1 and 3 months.
Results: In the WaveLight and Technolas groups, cylindrical refractive errors at month 3 were –0.92 ± 0.28 D and –0.88 ± 0.46 D,
respectively. Spherical equivalent values for the groups at month 3 were –0.38 ± 0.73 D and –0.33 ± 0.20 D, respectively. There was no
significant difference in postoperative uncorrected distance visual acuity at month 3 between the two groups (P = 0.671). At postoperative
month 3, 70% of patients treated with WaveLight and 100% of patients treated with Technolas had an uncorrected distance visual acuity
of 20/25 or better (P = 0.211).
Conclusion: There were no significant differences in refraction and visual acuity between the WaveLight and Technolas groups during
a 3-month follow-up period after laser in situ keratomileusis for mixed astigmatism.
Key words: Excimer laser, laser in situ keratomileusis, mixed astigmatism

1. Introduction
Today many excimer laser systems have software programs
for treating mixed astigmatism. Different approaches have
been reported: negative-cylinder nomogram, positivecylinder nomogram, cross-cylinder technique, bitoric
ablation, and sequential ablation. The common goal in the
treatment of mixed astigmatism is to remove the minimum
amount of tissue while achieving good visual results (1,2).
In mixed astigmatism, one focal line is projected in
front of the retina while the other focal line is projected
behind the retina. Therefore, the ablation profile of mixed
astigmatism is more complex (3). Myopia correction in one
meridian and hyperopia correction in the other meridian
are the goals (4). Thus, the results are less predictable
than those in the correction of simple or compound
astigmatism. Residual or induced astigmatism is usually a
frequent cause of patient dissatisfaction after laser in situ
keratomileusis (LASIK) for mixed astigmatism.
* Correspondence: ebrubahadir@gmail.com

664

To correct mixed astigmatism, the WaveLight Allegretto
Wave Eye-Q 400 Hz excimer laser (WaveLight GmbH,
Alcon, USA) uses the bitoric ablation profile. According
to the Food and Drug Administration (FDA) approved
indications for excimer lasers for LASIK management of
mixed astigmatism, up to 6.00 D of mixed astigmatism on
the spectacle plane is approved for WaveLight Allegretto
Wave excimer laser treatment (4). The Technolas 217z100
excimer laser (Bausch & Lomb, USA) uses sequential
ablation (Bausch & Lomb), in which the positive cylinder
is treated first and the negative sphere is treated later.
Therefore, the device uses two different nomograms
during the same surgical operation. The Technolas
217z100 excimer laser does not have FDA approval for
LASIK management of mixed astigmatism. In the present
paper the early clinical outcomes and the safety and
efficacy of these two laser systems are compared. To the
best of our knowledge, this paper is the first to compare

KILAVUZOĞLU et al. / Turk J Med Sci
two different ablation algorithms in LASIK treatment of
mixed astigmatism.
2. Materials and methods
The Institutional Review Board of Acıbadem University
granted approval for the present study. The medical records
of patients who underwent LASIK surgery using either the
WaveLight Allegretto Wave Eye-Q 400 Hz or Technolas
217z100 excimer laser at the Acıbadem Maslak Hospital
Eye Clinic from 1 January 2010 to 31 May 2014 were
evaluated retrospectively. All patients met the following
criteria: age >21 years, preoperative mixed and regular
astigmatism, and absence of corneal diseases. Exclusion
criteria included: a predicted residual stromal bed
thickness of <250 µm, suspicion of keratoconus, irregular
astigmatism, and previous ocular surgery. Written
informed consent related to the surgical procedures was
obtained from all patients prior to surgery.
All patients had a complete preoperative
ophthalmological examination, including uncorrected
distance visual acuity (UDVA), corrected distance visual
acuity (CDVA), manifest and cycloplegic refraction,
intraocular pressure (IOP) with air-puff tonometry (CT80, Topcon, Japan), corneal pachymetry and topography
(Pentacam, Oculus, Germany), scotopic pupil measurement
(Colvard pupillometer, Oasis, USA), and fundoscopy.
Surgeries were performed by two surgeons (CBCY and
ABŞ) at the Acıbadem Maslak Hospital Eye Clinic. After
topical anesthesia with 0.5% proparacaine hydrochloride
(Alcaine, Alcon Laboratories, USA), a sterile drape and
an eyelid speculum were positioned. A Hansatome XP
microkeratome (Bausch & Lomb) was used to create a
120-µm-thick corneal flap. The suction ring was selected
depending on the corneal diameter (8.5 mm or 9.5 mm).
After the flap was created, it was raised with a spatula.
The stromal bed was dried with a sponge and the ablation
was performed using either the WaveLight Allegretto
Wave Eye-Q 400 Hz or Technolas 217z100 excimer laser.
After the ablation, the stroma was washed with balanced
salt solution and the flap was repositioned with the help of
a cannula. One drop of 0.5% moxifloxacin hydrochloride
ophthalmic solution (Vigamox, Alcon Laboratories)
was applied at the end of the procedure. Postoperatively
Vigamox was prescribed 3 times daily for 5 days and 0.5%
loteprednol etabonate ophthalmic suspension (Lotemax,
Bausch & Lomb) was prescribed starting with 5 times
daily and tapering over 5 days. Preservative-free artificial
tears were used as needed. Patients were examined on
postoperative day 1 and at 1 and 3 months. UDVA,
CDVA, IOP, and objective and subjective refraction were
measured. Safety was calculated by the following equation:
postoperative CDVA/preoperative CDVA. Efficacy was
calculated by the following equation: postoperative
UDVA/preoperative CDVA.

SPSS 17.0 was used for the statistical analysis. Visual
acuity was converted to the logarithm of the minimum
angle of resolution from the decimal notation for
statistical analysis. Descriptive data were expressed as
mean ± SD. The chi-square and Fisher exact tests were
used to determine differences in categorical data. Data
normality was confirmed by the Kolmogorov–Smirnov
test. The WaveLight and Technolas groups were compared
by the Mann–Whitney U test. One-way ANOVA for
repeated measures was used to evaluate the changes in
spherical, cylindrical, and spherical equivalent values
postoperatively. P < 0.05 was considered significant.
3. Results
Twenty-eight eyes of 21 patients (13 females and 8
males) who were treated with the WaveLight Allegretto
Wave Eye-Q 400 Hz excimer laser (WaveLight group)
and 46 eyes of 28 patients (13 females and 15 males) who
were treated with the Technolas 217z100 excimer laser
(Technolas group) were included in the present study. The
patients in the WaveLight group met the FDA approved
criteria for LASIK management of mixed astigmatism. The
mean age was 35.62 ± 12.60 (21–66) years in the WaveLight
group and 34.29 ± 8.70 (21–66) years in the Technolas
group (P = 0.992). Demographic data and preoperative
mean IOP, UDVA, CDVA, spherical error, cylindrical
error, spherical equivalent, and central corneal thickness
values are shown in Table 1. There was no significant
difference in demographic data and preoperative values
between the two groups as shown in Table 1.
Mean UDVA, CDVA, sphere, cylinder, and spherical
equivalent values at postoperative day 1, month 1, and
month 3 in the WaveLight and Technolas groups are shown
in Table 2. The mean spherical and spherical equivalent
values were significantly lower in the Technolas group than
in the WaveLight group on postoperative day 1 (P = 0.043
and P = 0.017, respectively), but there was no significant
difference in visual and refractive results at postoperative
month 1 and month 3 between the two groups (P > 0.05),
as shown in Table 2 (Figures 1–3).
Patients with preoperative cylinder values of ≥5.00
D were excluded and further analyses were performed
with the remaining population (Table 3). There were no
significant differences regarding the mean cylindrical
refraction between the WaveLight group and the Technolas
group at postoperative month 1 and month 3 (P = 0.568
and P = 0.470, respectively).
The patients who had postoperative day 1, month 1, and
month 3 measurements were also analyzed for repeated
measurements of spherical, cylindrical, and spherical
equivalent values (Table 4). There was a significant
change in spherical values between postoperative day 1
and month 3 measurements in the Technolas group (P =
0.028). However, there were no significant regressions in
spherical, cylindrical, or spherical equivalent values from
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Table 1. Demographic data and preoperative values of eyes in the WaveLight and Technolas groups.
Variables

WaveLight (n = 28)

Technolas (n = 46)

P

Age (years)

35.62 ± 12.60 (21–66)

34.29 ± 8.70 (21–66)

0.992

Sex (F/M)

13/8

13/15

0.283

IOP (mmHg)

16.00 ± 3.17 (11–25)

15.84 ± 3.22 (11–23)

0.866

UDVA (decimal)

0.27 ± 0.16 (0.1–0.6)

0.28 ± 0.16 (0.1–0.7)

0.876

CDVA (decimal)

0.84 ± 0.22 (0.2–1.0)

0.83 ± 0.19 (0.2–1.0)

0.303

Sphere (D)

1.58 ± 1.02 (0.25–4.25)

1.67 ± 1.43 (0.25–5.25)

0.626

Cylinder (D)

–3.19 ± 1.19 (–5.25 to –1.25)

–3.62 ± 1.42 (–6.75 to –1.50)

0.274

SE (D)

–0.01 ± 1.04 (–2.38 to –1.88)

–0.14 ± 1.16 (–2.38 to 2.88)

0.349

CCT (µm)

553.96 ± 33.62 (496–622)

556.74 ± 36.37 (481–658)

0.806

F: female; M: male; IOP: intraocular pressure; UDVA: uncorrected distance visual acuity; CDVA: corrected distance visual acuity;
D: diopter; SE: spherical equivalent; CCT: central corneal thickness.
P: Mann–Whitney U test, chi-square test.
Table 2. Postoperative day 1, month 1, and month 3 results in the WaveLight and Technolas groups.
Follow-up visits

Variables

WaveLight

Technolas

Post-op day 1

n

28

46

UDVA (decimal)

0.80 ± 0.21

0.81 ± 0.21

0.825

CDVA (decimal)

0.88 ± 0.17

0.86 ± 0.19

0.585

Sphere (D)

–0.23 ± 0.67

0.06 ± 0.45

0.043

Cylinder (D)

–0.86 ± 0.52

–0.69 ± 0.43

0.157

SE (D)

–0.66 ± 0.72

–0.28 ± 0.41

0.017

n

19

23

UDVA (decimal)

0.81 ± 0.20

0.845

0.84 ± 0.20

0.205

Sphere (D)

0.81 ± 0.21
0.91 ± 0.16
(n = 14)
0.19 ± 0.50

0.40 ± 0.60

0.336

Cylinder (D)

–0.59 ± 0.74

–0.81 ± 0.44

0.409

SE (D)

–0.09 ± 0.63

–0.00 ± 0.46

0.559

n

10

9

UDVA (decimal)

0.88 ± 0.09

0.671

0.93 ± 0.10

0.529

Sphere (D)

0.81 ± 0.19
0.92 ± 0.18
(n = 7)
0.07 ± 0.78

0.11 ± 0.37

0.901

Cylinder (D)

–0.92 ± 0.28

–0.88 ± 0.46

1.000

SE (D)

–0.38 ± 0.73

–0.33 ± 0.20

0.562

Post-op month 1

CDVA (decimal)

Post-op month 3

CDVA (decimal)

P

UDVA: uncorrected distance visual acuity; CDVA: corrected distance visual acuity; D: diopter; SE: spherical equivalent;
P: Mann–Whitney U test. Bolded values are significant at P < 0.05.
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Figure 1. Spherical equivalent refractive accuracy at postoperative month 1 and month 3 in the WaveLight and Technolas groups.
A: Month 1; B: Month 3.
Refractive astigmatism at month 1
40%
35%

WaveLight Allegretto Wave
Eye-Q

30%

Technolas 217z100

% of eyes

% of eyes

40%
35%

25%
20%
15%

30%

WaveLight Allegretto Wave
Eye-Q

25%

Technolas 217z100

20%
15%

10%

10%

5%

5%

0%

0%
≤
0.25

A

0.26
to
0.50

0.51 0.76 1.01 1.26
to
to
to
to
0.75 1.00 1.25 1.50
Refractive astigmatism (D)

1.51
to
2.00

Refractive astigmatism at month 3

45%

2.01
to
3.00

≤
0.25

B

0.26
to
0.50

0.51
to
0.75

0.76
to
1.00

1.01
to
1.25

1.26
to
1.50

1.51
to
2.00

2.01
to
3.00

Refractive astigmatism (D)

2

28 eyes
3 months post-op

% changed > 0.50 D
1–3 months = 3.4%

1

0

–1

–2

Pre

Day 1 (28) Month 1 (19) Month 3 (10)
A
Time after surgery

Mean ± S D s p h e ric a l e q u iv a le n t refraction (D)

Mean ± S D s p h e ric a l e q u iv a le n t refraction (D)

Figure 2. Refractive astigmatism at postoperative month 1 and month 3 in the WaveLight and Technolas groups. A: Month 1; B: Month 3.

B

46 eyes
3 months post-op

% changed > 0.50 D
1–3 months = 0%

2

1

0

–1

–2

Pre

Day1 (44)

Month1 (23)
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Figure 3. Stability of spherical equivalent refraction after laser in situ keratomileusis in the WaveLight and Technolas groups. A:
WaveLight group; B: Technolas group.
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Table 3. Comparisons of mean cylinder outcomes in the WaveLight group and the Technolas group after excluding patients with
preoperative cylinder refraction of ≥5.00 D.
Cylinder (D)

WaveLight (n)

Technolas (n)

P

Preoperative

–3.04 ± 1.10 (26)

–2.97 ± 0.85 (35)

0.815

Post-op day 1

–0.85 ± 0.52 (26)

–0.56 ± 0.31 (33)

0.049

Post-op month 1

–0.54 ± 0.72 (18)

–0.70 ± 0.34 (17)

0.568

Post-op month 3

–0.88 ± 0.28 (9)

–0.96 ± 0.50 (7)

0.470

D: diopter.
P: Mann–Whitney U test. Bolded values are significant at P < 0.05.
Table 4. Postoperative changes in spherical, cylindrical, and spherical equivalent values in the WaveLight and Technolas groups.

WaveLight

Technolas

Variables

Post-op day 1

Post-op month 1

Post-op month 3

P

n

8

8

8

Sphere (D)

0.00 ± 0.84

0.34 ± 0.61

0.18 ± 0.84

0.076

Cylinder (D)

–1.00 ± 0.48

–0.90 ± 0.37

–0.96 ± 0.28

0.420

SE (D)

–0.54 ± 0.97

–0.10 ± 0.58

–0.29 ± 0.80

0.057

n

9

9

9

Sphere (D)

–0.11 ± 0.41

–0.05 ± 0.30

0.11 ± 0.37

0.036

Cylinder (D)

–0.69 ± 0.30

–0.66 ± 0.43

–0.88 ± 0.46

0.150

SE (D)

–0.45 ± 0.38

–0.38 ± 0.18

–0.33 ± 0.20

0.527

D: diopter; SE: spherical equivalent.
P: One-way ANOVA for repeated measures, bolded values are significant for P < 0.05.

postoperative month 1 to month 3 in the WaveLight group
or the Technolas group (P > 0.05).
At postoperative month 3, 70% of patients in the
WaveLight group and 100% of patients in the Technolas
group had UDVA of 20/25 or better (P = 0.211) (Table 5;
Figure 4). At month 1, two eyes lost ≥1 line(s) of CDVA and
3 eyes gained ≥1 line(s) of CDVA in the WaveLight group
(n = 14). In the Technolas group 2 eyes lost 1 line of CDVA
and 5 eyes gained ≥1 line(s) of CDVA (n = 23) (Figure 5).
At month 3, none of the eyes lost any lines of CDVA and
2 eyes gained ≥2 lines of CDVA in the WaveLight group
(n = 7). In the Technolas group at month 3, none of the
eyes lost any lines of CDVA and 2 eyes gained ≥1 line(s) of
CDVA (n = 9) (Figure 5). No significant differences were
observed between the two groups regarding the loss or
gain of lines of CDVA at month 1 and month 3 (P > 0.05).
At month 1 in the WaveLight vs. the Technolas
group, spherical equivalent refraction was within ±0.50
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D of emmetropia in 14 patients (73.7%) vs. 17 patients
(73.9%) (P = 1.000), and the cylinder was within ±0.50 D
in 7 patients (36.8%) vs. 10 patients (43.5%) (P = 0.757)
(Table 6), respectively. At month 3 in the WaveLight vs.
the Technolas group, spherical equivalent refraction was
within ±0.50 D of emmetropia in 4 patients (40%) vs. 7
patients (77.8%) (P = 0.170), and the cylinder was within
±0.50 D in 1 patient (10%) vs. 3 patients (33.3%) (P =
0.303) (Table 6), respectively. The relationships between
attempted and achieved corrections in the WaveLight
group and the Technolas group at month 3 are shown in
Figure 6.
At month 3, safety was 1.09 ± 0.17 (1.00–1.43) for
the WaveLight group and 1.06 ± 0.14 (1.00–1.43) for the
Technolas group (P = 0.728). At month 3, efficacy was
1.18 ± 0.48 (0.90–2.50) for the WaveLight group and 1.00
± 0.08 (0.90–1.14) for the Technolas group (P = 0.637).
No intraoperative or postoperative complications were
reported for either group.
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Table 5. Cumulative visual acuities at month 1 and month 3 postoperatively in the WaveLight and Technolas groups.
Follow-up visits

Visual acuities

WaveLight

Technolas

Post-op month 1

n

19

23

UDVA ≥ 20/20

6 (31.6%)

7 (30.4%)

1.000

UDVA ≥ 20/25

13 (68.4%)

17 (73.9%)

0.742

UDVA ≥ 20/32

14 (73.7%)

19 (82.6%)

0.707

n

10

9

UDVA ≥ 20/20

2 (20%)

3 (33.3%)

0.628

UDVA ≥ 20/25

7 (70%)

9 (100%)

0.211

UDVA ≥ 20/32

7 (70%)

9 (100%)

0.211

Post-op month 3

P

UDVA: uncorrected distance visual acuity.
P: Fisher’s exact test.

Uncorrected distance visual acuity
(Technolas 217z100)

A

100
90
80
70
Pre-op60
CDVA
50
Post-op 1st day UDVA
40
Post-op
301st month UDVA
Post-op
203rd month UDVA
10
0
20/20 20/25 20/32 20/40 20/80 20/100
Cumulative visual acuity
B
Cumula tive % o f e ye s

Cu m u l a t i v e % o f e y e s

100
90
80
70
60
50
40
30
20
10
0

Uncorrected distance visual acuity
(WaveLight Allegretto Wave Eye-Q)

20/20

20/25 20/32 20/40 20/80
Cumulative visual acuity

20/100

Pre-op CDVA
Post-op 1st day UDVA
Post-op 1st month UDVA
Post-op 3rd month UDVA

Figure 4. Preoperative and postoperative cumulative visual acuities of patients in the WaveLight and Technolas groups. A: WaveLight
group; B: Technolas group.

Change in corrected distance visual acuity at postoperative month 1
80%
70%

Technolas 217z100

50%

% of eyes

% of eyes

60%

Wavelight Allegretto Wave
Eye-Q

40%
30%
20%

WaveLight Allegretto Wave
Eye-Q
Technolas 217z100

30%
20%
10%
0%

10%
0%

A

90%
80%
70%
60%
50%
40%

Change in corrected distance visual acuity at
postoperative month 3

Change in Snellen lines of CDVA

B

Change in Snellen lines of CDVA

Figure 5. Change in the corrected distance visual acuity at postoperative month 1 and month 3 in the WaveLight and Technolas groups.
A: Month 1; B: Month 3.
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Table 6. Refractive results after laser in situ keratomileusis in the WaveLight and Technolas groups.
Follow-up visits

Refractive results

WaveLight

Technolas

Post-op day 1

n

28

44

Eyes within ±0.50 D SE

13 (46.4%)

28 (63.6%)

0.222

Eyes within ±1.00 D SE

18 (64.3%)

44 (100%)

0.000

Eyes within ±0.50 D cylinder

12 (42.9%)

22 (50%)

0.632

n

19

23

Eyes within ±0.50 D SE

14 (73.7%)

17(73.9%)

1.000

Eyes within ±1.00 D SE

16 (84.2%)

23 (100%)

0.084

Eyes within ±0.50 D cylinder

7 (36.8%)

10 (43.5%)

0.757

n

10

9

Eyes within ±0.50 D SE

4 (40%)

7 (77.8%)

0.170

Eyes within ±1.00 D SE

9 (90%)

9 (100%)

1.000

Eyes within ±0.50 D cylinder

1 (10%)

3 (33.3%)

0.303

Post-op month 1

Post-op month 3

P

D: diopter; SE: spherical equivalent.
P: Fisher’s exact test. Bolded values are significant at P < 0.05.
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R² = 0.5549
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Attempted spherical equivalent refraction (D)
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Figure 6. Attempted vs. achieved spherical equivalent refraction at postoperative month 3 in the WaveLight and Technolas groups.
A: WaveLight group; B: Technolas group.

4. Discussion
Mixed astigmatism can be surgically managed by
astigmatic keratotomy and/or LASIK. However, poor
predictability (5–8) and complications of astigmatic
keratotomy led refractive surgeons to use LASIK as a
standard surgical option. There are different techniques
for LASIK correction of mixed astigmatism, including
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negative-cylinder
nomogram,
positive-cylinder
nomogram, bitoric ablation, cross-cylinder ablation, and
sequential ablation. In a negative-cylinder nomogram
central ablation is performed along the steepest meridian.
This also induces some flattening of the flattest meridian
(2). In a positive-cylinder nomogram, the flattest meridian
is steepened. Since ablation is not performed in the central
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cornea, no significant effect on the steepest meridian is
observed (9). The bitoric ablation technique flattens the
steepest meridian with a central cylindrical ablation and
steepens the flattest meridian with a paracentral ablation.
This technique has the advantages of correcting the same
refractive error with less tissue removal (10). In crosscylinder ablation the treatment is split into three parts:
two symmetrical cylinder treatments of opposed signs (a
negative and a positive cylinder in equal parts), followed
by a spherical component treatment (11). In the sequential
ablation technique, the positive cylinder is treated first
and full astigmatism is corrected. A purely myopic eye is
obtained and then the negative sphere is treated (2).
Different laser systems use these techniques aiming
at less tissue ablation with better postoperative visual
and refractive results. Postoperative spherical equivalent
values within 0.50 D or 1.00 D, cylindrical values within
0.50 D, and efficacy of ≥1.00 generally mean good visual
outcomes (12–15). To date, for LASIK treatment of mixed
astigmatism the results of one laser system (2,8,9,14,16–
19) or two related laser systems (1,20) have been reported.
In the present study we compared the early clinical
outcomes of two different laser systems in treating mixed
astigmatism for the first time in the literature.
Stonecipher et al. (1) reported that 81% (n = 21) of
eyes had UDVA of 20/20 or better with the WaveLight
Allegretto Wave 400 Hz excimer laser at postoperative
month 3. Albarran-Diego et al. (9) reported that 21% of
eyes treated with the Chiron Technolas 217 excimer laser
had UDVA of 20/20 or better following surgery. In the
present study, the frequency of postoperative UDVA of
≥20/20 was 31.6% and 20% in the WaveLight group and
30.3% and 33.3% in the Technolas group at postoperative
month 1 and month 3, respectively. The postoperative low
visual acuities may be attributed to the relatively higher
preoperative cylindrical errors. We also found that UDVA
following surgery was better than CDVA prior to surgery.
At postoperative month 3, the mean efficacy was ≥1.00 for
both the WaveLight and the Technolas groups. Pinelli et al.
(2) reported that the efficacy was ≥1.00 in all eyes with the
Technolas 217 excimer laser.
In the present study at month 3, none of the eyes lost
any lines of CDVA and 2 eyes (28.5%) gained ≥2 lines of
CDVA in the WaveLight group. In the Technolas group,
none of the eyes lost any lines of CDVA and 2 eyes (20%)
gained ≥1 line(s) of CDVA. Stonecipher et al. (1) reported
that at 3 months postoperatively, no eyes lost any lines of
CDVA and 3 eyes (12%) gained 1 line with the WaveLight
Allegretto Wave 400 Hz excimer laser. Pinelli et al. (2)
reported that there was no loss of lines of CDVA and 16
(40%) eyes gained 1 line in CDVA at postoperative 1 year
with the Technolas 217 excimer laser.
In the present study from month 1 to month 3, there
was a tendency of myopic regression in the mean spherical

equivalent refraction in the WaveLight group (from –0.10
± 0.58 D at month 1 to –0.29 ± 0.80 D at month 3) and
myopic regression in the mean cylinder in the Technolas
group (from –0.66 ± 0.43 D at month 1 to –0.88 ± 0.46 D at
month 3), but these were not significant (Table 4; P = 0.057
and P = 0.150, respectively). Although not significant,
these regressions may be clinically important and
additional research with a larger population is required to
more clearly discern if this is true.
All eyes had a mean spherical equivalent refraction
within ±0.50 D of the intended correction and the
residual astigmatism was ≤0.50 D in all eyes treated
with the WaveLight Allegretto Wave 400 Hz in the study
by Stonecipher et al. (1). Pinelli et al. (2) reported that
80% of patients (n = 32) treated with the Technolas 217
excimer laser had no residual astigmatism (≤0.50 D)
and the remaining 20% (n = 8) had residual astigmatism
between 0.50 D and 1.00 D. We found that at postoperative
month 3, one eye in the WaveLight group and 3 eyes in
the Technolas group had no residual astigmatism (P =
0.213). Spherical equivalent values were –0.38 ± 0.73 D in
the WaveLight group and –0.33 ± 0.20 D in the Technolas
group (P = 0.562). Although not significant, there was
a tendency of myopic undercorrection of the spherical
equivalent refraction in the WaveLight group (Table 2).
Moreover, after excluding the patients with preoperative
cylinder refraction of ≥5.00 D, analyses showed that the
patients in the Technolas group had a tendency to have
higher residual astigmatism at postoperative month 1
and month 3 (Table 3). These findings may be clinically
significant and must be further evaluated with additional
research with a larger population.
In conclusion, the results presented in the present study
indicate that both laser systems are effective and safe for
the correction of mixed astigmatism. In terms of surgical
technique, none of the laser systems had an advantage over
the other. The WaveLight Allegretto Wave Eye-Q 400 Hz
excimer laser seems to have better refractive outcomes
regarding cylindrical refraction, and the Technolas
217z100 excimer laser seems to have better outcomes
regarding spherical equivalent refraction. However, a
larger group of patients with a longer follow-up period
is necessary to more clearly discern if this is true and to
compare the stability of the results of these laser systems.
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